To date, germline RAD51D mutations have only been associated with increased risk of ovarian cancer and ATM germline mutations have primarily been shown to increased risk of breast cancer as well as case familial cases of ovarian, prostate, and pancreatic cancers. This evidence concerns the gene RAD51D and breast cancer.